PCSK9 Inhibitors in the Management of Cardiovascular Risk: A Practical Guidance

Xiaoming Jia, Mahmoud Al Rifai, Anum Saeed, Christie M. Ballantyne, Salim S. Virani

Research output: Contribution to journalReview articlepeer-review

7 Citations (Scopus)


Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are potent medications in the toolkit for treatment of atherosclerotic cardiovascular disease. These agents have been well studied in clinical trials supporting their efficacy in dramatically reducing low-density lipoprotein cholesterol (LDL-C) and impact on cardiovascular outcomes. Since the approval of commercial use for PCSK9 inhibitors in 2015, we have also gained significant experience in the use of these therapeutics in the real-world setting. In this article, we review current guideline recommendations, clinical trial evidence on efficacy and safety as well as data on cost-effectiveness, prescription and adherence. We focus primarily on the monoclonal antibody class of PCSK9 inhibitors in this review while also touching on other types of therapeutics that are under development.

Original languageEnglish
Pages (from-to)555-566
Number of pages12
JournalVascular Health and Risk Management
Publication statusPublished - 2022
Externally publishedYes


  • CVD prevention
  • PCSK9 inhibitor
  • lipids


Dive into the research topics of 'PCSK9 Inhibitors in the Management of Cardiovascular Risk: A Practical Guidance'. Together they form a unique fingerprint.

Cite this